Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $8.50.

GANX has been the subject of several recent research reports. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Weiss Ratings downgraded Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Oppenheimer reaffirmed an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. Finally, Roth Mkm reissued a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Apollon Wealth Management LLC boosted its stake in Gain Therapeutics by 33.7% in the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after purchasing an additional 6,675 shares in the last quarter. Geode Capital Management LLC increased its stake in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares in the last quarter. Sprott Inc. purchased a new position in Gain Therapeutics in the fourth quarter worth about $39,000. Commonwealth Equity Services LLC purchased a new position in Gain Therapeutics in the fourth quarter worth about $41,000. Finally, Millennium Management LLC bought a new position in shares of Gain Therapeutics in the fourth quarter worth approximately $45,000. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Stock Down 1.1%

Shares of Gain Therapeutics stock opened at $1.72 on Friday. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $4.34. The firm has a market cap of $73.36 million, a price-to-earnings ratio of -2.97 and a beta of 0.16. The company has a 50-day moving average of $1.83 and a 200 day moving average of $2.20. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.69 and a quick ratio of 4.69.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). During the same quarter in the prior year, the business posted ($0.16) EPS. As a group, sell-side analysts anticipate that Gain Therapeutics will post -0.54 earnings per share for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.